Preclinical Alzheimer&#039;s disease: Definition, natural history, and diagnostic criteria

Dubois, Bruno; Hampel, Harald; Feldman, Howard H.; Scheltens, Philip; Aisen, Paul; Andrieu, Sandrine; Bakardjian, Hovagim; Benali, Habib; Bertram, Lars; Blennow, Kaj; Broich, Karl; Cavedo, Enrica; Crutch, Sebastian; Dartigues, Jean-François; Duyckaerts, Charles; Epelbaum, Stéphane; Frisoni, Giovanni; Gauthier, Serge; Genthon, Remy; Gouw, Alida A.; Habert, Marie-Odile; Holtzman, David M.; Kivipelto, Miia; Lista, Simone; Molinuevo, José-Luis; O'Bryant, Sid E.; Rabinovici, Gil D.; Rowe, Christopher; Salloway, Stephen; Schneider, Lon S.; Sperling, Reisa; Teichmann, Marc; Carrillo, Maria C.; Cummings, Jeffrey; Jack, Cliff R.

doi:10.1016/j.jalz.2016.02.002

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
Authors		Dubois, Bruno Hampel, Harald Feldman, Howard H. Scheltens, Philip Aisen, Paul Andrieu, Sandrine Bakardjian, Hovagim Benali, Habib Bertram, Lars Blennow, Kaj Broich, Karl Cavedo, Enrica Crutch, Sebastian Dartigues, Jean-François Duyckaerts, Charles Epelbaum, Stéphane Frisoni, Giovanni Gauthier, Serge Genthon, Remy Gouw, Alida A. Habert, Marie-Odile Holtzman, David M. Kivipelto, Miia Lista, Simone Molinuevo, José-Luis O'Bryant, Sid E. Rabinovici, Gil D. Rowe, Christopher Salloway, Stephen Schneider, Lon S. Sperling, Reisa Teichmann, Marc Carrillo, Maria C. Cummings, Jeffrey Jack, Cliff R. show all authors [1 - 35]
Published in		Alzheimer's & Dementia. 2016, vol. 12, no. 3, p. 292-323
Abstract		During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this "silent" stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
Keywords		Alzheimer's disease — Amyloid PET — Asymptomatic — Biomarkers — Blood biomarkers — CSF biomarkers — Diagnostic criteria — Genetics — MRI — Pathophysiology — Preclinical — Tau PET
Identifiers		DOI: 10.1016/j.jalz.2016.02.002
Full text		Article (Published version) (1.1 MB) - Limited access to UNIGE Other version: http://linkinghub.elsevier.com/retrieve/pii/S1552526016000509
Structures		Faculté de médecine / Section de médecine clinique / Département de psychiatrie
Research group		Troubles de mémoire et maladie d'Alzeimer (935)
Citation (ISO format)		DUBOIS, Bruno et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. In: Alzheimer's & Dementia, 2016, vol. 12, n° 3, p. 292-323. doi: 10.1016/j.jalz.2016.02.002 https://archive-ouverte.unige.ch/unige:83551